Financial and HR benchmarking of a cancer immunotherapy company
Challenge
A well-capitalized cancer immunotherapy company, operating in a highly competitive field, needed to benchmark its financial status and staff numbers against its peers to help gauge its competitive positioning and future financing needs.
Solution
Our cancer immunotherapy consulting team worked with the client to develop a list of comparable companies in the CAR-T and cancer immunotherapy space against which our client could be benchmarked. By analyzing SEC filings, company annual reports and other sources, we gathered extensive data about each of the companies and prepared a detailed report comparing our client to other companies across several different metrics.
We compared employee growth over time in different roles, expenditure per employee, research expenditures versus G&A expenditures, and the growth in employee number and expenditures in view of total fundraising. The completed report was presented at a company board meeting to help understand the competitive landscape and possible future strategic funding requirements.
View Additional Immunotherapy Case Studies
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Pre-Due Diligence Assessment of First-in-Class Allergy Therapeutic
Strategic Partnership Assessment of Autoimmune Drug Development Program
Pre-Due Diligence Assessment of a Women's Health Biotech Partnership
Due Diligence of an Academic Adenovirus Gene-Therapy Program
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.